343 related articles for article (PubMed ID: 38384471)
1. Epstein-Barr virus: the mastermind of immune chaos.
Silva JM; Alves CEC; Pontes GS
Front Immunol; 2024; 15():1297994. PubMed ID: 38384471
[TBL] [Abstract][Full Text] [Related]
2. The Epstein-Barr Virus Oncogene EBNA1 Suppresses Natural Killer Cell Responses and Apoptosis Early after Infection of Peripheral B Cells.
Westhoff Smith D; Chakravorty A; Hayes M; Hammerschmidt W; Sugden B
mBio; 2021 Dec; 12(6):e0224321. PubMed ID: 34781735
[TBL] [Abstract][Full Text] [Related]
3. T cell-mediated immunity during Epstein-Barr virus infections in children.
Liu M; Wang R; Xie Z
Infect Genet Evol; 2023 Aug; 112():105443. PubMed ID: 37201619
[TBL] [Abstract][Full Text] [Related]
4. Immune Evasion by Epstein-Barr Virus.
Ressing ME; van Gent M; Gram AM; Hooykaas MJ; Piersma SJ; Wiertz EJ
Curr Top Microbiol Immunol; 2015; 391():355-81. PubMed ID: 26428381
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr Virus-Specific CD8 T Cells Selectively Infiltrate the Brain in Multiple Sclerosis and Interact Locally with Virus-Infected Cells: Clue for a Virus-Driven Immunopathological Mechanism.
Serafini B; Rosicarelli B; Veroni C; Mazzola GA; Aloisi F
J Virol; 2019 Dec; 93(24):. PubMed ID: 31578295
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr Virus miR-BART6-3p Inhibits the RIG-I Pathway.
Lu Y; Qin Z; Wang J; Zheng X; Lu J; Zhang X; Wei L; Peng Q; Zheng Y; Ou C; Ye Q; Xiong W; Li G; Fu Y; Yan Q; Ma J
J Innate Immun; 2017; 9(6):574-586. PubMed ID: 28877527
[TBL] [Abstract][Full Text] [Related]
7. Innate Immune Recognition of EBV.
Lünemann A; Rowe M; Nadal D
Curr Top Microbiol Immunol; 2015; 391():265-87. PubMed ID: 26428378
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr Virus Envelope Glycoprotein gp110 Inhibits IKKi-Mediated Activation of NF-κB and Promotes the Degradation of β-Catenin.
Guo Y; Pan L; Wang L; Wang S; Fu J; Luo W; Wang K; Li X; Huang C; Liu Y; Kang H; Zeng Q; Fu X; Huang Z; Li W; He Y; Li L; Peng T; Yang H; Li M; Xiao B; Cai M
Microbiol Spectr; 2023 Jun; 11(3):e0032623. PubMed ID: 37022262
[TBL] [Abstract][Full Text] [Related]
9. Immunity and Immune Evasion Mechanisms of Epstein-Barr Virus.
Yao Y; Kong W; Yang L; Ding Y; Cui H
Viral Immunol; 2023 Jun; 36(5):303-317. PubMed ID: 37285188
[TBL] [Abstract][Full Text] [Related]
10. A Mechanism-Based Targeted Screen To Identify Epstein-Barr Virus-Directed Antiviral Agents.
Li X; Akinyemi IA; You JK; Rezaei MA; Li C; McIntosh MT; Del Poeta M; Bhaduri-McIntosh S
J Virol; 2020 Oct; 94(21):. PubMed ID: 32796077
[TBL] [Abstract][Full Text] [Related]
11. MicroRNAs of Epstein-Barr Virus Attenuate T-Cell-Mediated Immune Control
Murer A; Rühl J; Zbinden A; Capaul R; Hammerschmidt W; Chijioke O; Münz C
mBio; 2019 Jan; 10(1):. PubMed ID: 30647153
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus large tegument protein BPLF1 contributes to innate immune evasion through interference with toll-like receptor signaling.
van Gent M; Braem SG; de Jong A; Delagic N; Peeters JG; Boer IG; Moynagh PN; Kremmer E; Wiertz EJ; Ovaa H; Griffin BD; Ressing ME
PLoS Pathog; 2014 Feb; 10(2):e1003960. PubMed ID: 24586164
[TBL] [Abstract][Full Text] [Related]
13. Epigenetics of Epstein Barr virus - A review.
Shareena G; Kumar D
Biochim Biophys Acta Mol Basis Dis; 2023 Dec; 1869(8):166838. PubMed ID: 37544529
[TBL] [Abstract][Full Text] [Related]
14. The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination.
Jochum S; Moosmann A; Lang S; Hammerschmidt W; Zeidler R
PLoS Pathog; 2012; 8(5):e1002704. PubMed ID: 22615564
[TBL] [Abstract][Full Text] [Related]
15. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus.
Hislop AD; Taylor GS; Sauce D; Rickinson AB
Annu Rev Immunol; 2007; 25():587-617. PubMed ID: 17378764
[TBL] [Abstract][Full Text] [Related]
16. Impaired Epstein-Barr virus-specific CD8+ T-cell function in X-linked lymphoproliferative disease is restricted to SLAM family-positive B-cell targets.
Hislop AD; Palendira U; Leese AM; Arkwright PD; Rohrlich PS; Tangye SG; Gaspar HB; Lankester AC; Moretta A; Rickinson AB
Blood; 2010 Oct; 116(17):3249-57. PubMed ID: 20644117
[TBL] [Abstract][Full Text] [Related]
17. Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases.
Cui X; Snapper CM
Front Immunol; 2021; 12():734471. PubMed ID: 34691042
[TBL] [Abstract][Full Text] [Related]
18. Histone Loaders CAF1 and HIRA Restrict Epstein-Barr Virus B-Cell Lytic Reactivation.
Zhang Y; Jiang C; Trudeau SJ; Narita Y; Zhao B; Teng M; Guo R; Gewurz BE
mBio; 2020 Oct; 11(5):. PubMed ID: 33109754
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus immunossuppression of innate immunity mediated by phagocytes.
Savard M; Gosselin J
Virus Res; 2006 Aug; 119(2):134-45. PubMed ID: 16545476
[TBL] [Abstract][Full Text] [Related]
20. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
